Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect

Arakawa,Maki; Nakamura,Kogenta; Yamada,Yoshiaki; Kato,Kimihito; Katsuda,Remi; Tobiume,Motoi; Zennami,Kenji; Watanabe,Masayuki; Kato,Yoshiharu; Nishikawa,Genya; Yoshizawa,Takahiko; Aoki,Shigeyuki; Taki,Tomohiro; Mitsui,Kenji; Honda,Nobuaki; Saito,Hiroko; Hasegawa,Takaaki

doi:10.3892/etm.2011.315

Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect

Authors:
- Maki Arakawa
- Kogenta Nakamura
- Yoshiaki Yamada
- Kimihito Kato
- Remi Katsuda
- Motoi Tobiume
- Kenji Zennami
- Masayuki Watanabe
- Yoshiharu Kato
- Genya Nishikawa
- Takahiko Yoshizawa
- Shigeyuki Aoki
- Tomohiro Taki
- Kenji Mitsui
- Nobuaki Honda
- Hiroko Saito
- Takaaki Hasegawa
View Affiliations

Affiliations: Department of Hospital Pharmacy, Aichi Medical University School of Medicine, Aichi-gun, Aichi 480-1195, Japan, Department of Urology, Aichi Medical University School of Medicine, Aichi-gun, Aichi 480-1195, Japan, Department of Pharmacy, Ichinomiya Municipal Hospital, Ichinomiya, Japan, Department of Urology, Tokoname Municipal Hospital, Tokoname, Aichi, Japan
Published online on: June 30, 2011 https://doi.org/10.3892/etm.2011.315
Pages: 901-905

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the relationship between tissue concentrations and exposure times or therapeutic effect of an anthracycline anticancer drug, pirarubicin, in bladder cancer tissue after single intravesical administration against superficial bladder cancer. The concentrations of pirarubicin in tumor tissues and serum were measured at designated collection times after a single intravesical administration of pirarubicin (30 mg) in 22 patients with superficial bladder cancer. A wide range of concentrations of pirarubicin in bladder cancer tissue was observed (2.3-125 µg/g of tissue), although serum pirarubicin concentrations were not detected in any of the patients. Recurrence of superficial bladder cancer after transurethral resection of the bladder tumor (TUR-BT) was observed in 2 patients (9%). The concentration of pirarubicin in the tumor tissue tended to be higher as the exposure time increased. There was a weak relationship between the pirarubicin tissue concentration and tumor size. However, no significant relationship between tissue pirarubicin concentrations and the prophylactic effect against intravesical recurrence of bladder cancer after TUR-BT was observed. All patients had no adverse events, such as bladder irritation and local toxicity, caused by the treatment with pirarubicin. These findings suggest that prior to single intravesical administration of pirarubicin to patients with superficial bladder cancer the exposure time and tumor size should be considered.

View Figures

View References

1.	Lutzeyer W, Rubben H and Dahm H: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 127:250–252. 1982.PubMed/NCBI
2.	Herr HW, Laudone VP and Whitmore WF: An overview of intravesical therapy for superficial bladder tumors. J Urol. 138:1363–1368. 1987.PubMed/NCBI
3.	Miki T, Nonomura N, Kojima Y, et al: A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer. Hinyokika Kiyo. 43:907–912. 1997.(In Japanese).
4.	Sylvester RJ, van der MA and Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 168:1964–1970. 2002. View Article : Google Scholar
5.	Lamm DL, Blumenstein BA, Crawford ED, et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 325:1205–1209. 1991.PubMed/NCBI
6.	Witjes JA, Meijden AP, Sylvester LC, Debruyne FM, van Aubel A and Withes WP: Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacilli Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology. 52:403–410. 1998.
7.	Soloway MS, Sofer M and Vaidya A: Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 167:1573–1583. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B and Sylvester R; Members of the European Organization for Research and Treatment of Cancer Genitourinary Group: A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 149:749–752. 1993.
9.	Tolley DA, Parmar MK, Grigor KM, et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol. 155:1233–1238. 1996.PubMed/NCBI
10.	Rajala P, Liukkonen T, Raitanen M, Rintala E, Kaasinen E, Helle M and Lukkarinen O: Transurethral resection with perioperative instillation of interferon-α or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol. 161:1133–1136. 1999.
11.	Solsona E, Iborra I, Ricós JV, Monrós L, Casanova J and Dumont R: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol. 161:1120–1123. 1999. View Article : Google Scholar
12.	Zincke H, Utz DC, Taylor WF, Myers RP and Leary FJ: Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized double-blind, controlled trial. J Urol. 129:505–509. 1983.
13.	Prout GR, Koontz WW, Coomms LJ, Hawkins IR and Friedell GH: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol. 130:677–680. 1983.PubMed/NCBI
14.	Fukushima T, Ueda T and Nakamura T: Pharmacokinetics and action mechanism of anthracyclines. Gan To Kagaku Ryoho. 19:445–450. 1992.(In Japanese).
15.	Akaza H, Niijima T, Hisamatsu T and Fujigaki M: Comparative investigation on use of (2′′R)-4′-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. Urology. 32:141–145. 1988.
16.	Kunimoto S, Miura K, Takahashi Y, Takeuchi T and Umezawa H: Rapid uptake by cultured tumor cells and intracellular behavior of 4-O-tetrahydropyranyladriamycin. J Antibiot. 36:3123–3117. 1983.(In Japanese).
17.	Okamura K, Ono Y, Kinukawa T, et al: Nagoya University Urological Oncology Group. Randomized study of single early instillation of (2′′R)-4-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer. 94:2363–2368. 2002.PubMed/NCBI
18.	Nakagawa S, Kojima M, Takeda H, Sugimoto K, Mikami K and Watanabe H: Short-duration bladder instillation therapy with pirarubicin for superficial bladder tumor based on pharmacodynamic study. Gan To Kagaku Ryoho. 19:1837–1877. 1992.(In Japanese).
19.	Sugano O, Hatakeyama T and Kato H: Investigation of retention time of intravesical instillation therapy with pirarubicin (THP). Gan To Kagaku Ryoho. 23:1169–1174. 1996.(In Japanese).
20.	Kanayama H, Yokota K, Kurokawa Y, et al: Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer. Gan To Kagaku Ryoho. 26:651–655. 1999.(In Japanese).
21.	Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K and Wada M: Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des. 14:123–131. 1999.PubMed/NCBI
22.	Hasegawa S, Abe T, Naito S, et al: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer. 71:907–913. 1995. View Article : Google Scholar
23.	Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J and Tsuruo T: Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ ADM. J Urol. 148:441–445. 1992.PubMed/NCBI
24.	Naito S, Kotoh S, Omoto T, et al: The Kyushu University Urological Oncology Group: Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. Cancer Chemother Pharmacol. 42:367–372. 1998.
25.	Tada Y, Wada M, Migita T, et al: Inceased expression of multidrug resistance-associated proteins in bladder cancer drug clinical course and drug resistance to doxorubicin. Int J Cancer. 98:630–635. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S and Shima H: Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells. J Infect Chemother. 17:11–16. 2010. View Article : Google Scholar
27.	Yamamoto Y, Nasu Y, Saika T, Aaeda T, Tsushima T and Kumon H: The absorption of pirarubicin instilled intravesicaly immediately after transurethral resection of superficial bladder cancer. BJU Int. 86:802–804. 2000. View Article : Google Scholar : PubMed/NCBI